Lupin Limited (NSE:LUPIN)
2,135.20
-17.60 (-0.82%)
At close: Feb 1, 2026
Lupin Revenue
Lupin had revenue of 70.48B INR in the quarter ending September 30, 2025, with 24.23% growth. This brings the company's revenue in the last twelve months to 247.51B, up 15.49% year-over-year. In the fiscal year ending March 31, 2025, Lupin had annual revenue of 227.08B with 13.48% growth.
Revenue (ttm)
247.51B
Revenue Growth
+15.49%
P/S Ratio
3.95
Revenue / Employee
10.31M
Employees
24,006
Market Cap
977.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 325.14B |
| Cipla | 279.67B |
| Zydus Lifesciences | 244.94B |
| Glenmark Pharmaceuticals | 166.79B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |
| Divi's Laboratories | 100.29B |
| Ipca Laboratories | 93.59B |
Lupin News
- 11 days ago - Lupin shares in focus today as company sign license and supply agreement for Semaglutide across 23 countries - Business Upturn
- 6 weeks ago - Lupin signs exclusive licensing agreement with Neopharmed for Plasil in Philippines and Brazil - Business Upturn
- 6 weeks ago - Lupin receives positive CHMP opinion for biosimilar ranibizumab Ranluspec in Europe - Business Upturn
- 6 weeks ago - Lupin receives US FDA EIR with VAI classification for Nagpur injectable facility - Business Upturn
- 6 weeks ago - Lupin gets SBTi Validation for emission reduction targets across all emission scopes - Business Upturn
- 7 weeks ago - Lupin subsidiary forms long-term strategic alliance with PolyPeptide Group to strengthen global peptide supply chain - Business Upturn
- 2 months ago - Lupin receives U.S. FDA tentative approval for generic Siponimod tablets - Business Upturn
- 2 months ago - Lupin signs exclusive licensing agreement with Valorum Biologics for biosimilar Armlupeg in the US - Business Upturn